Search

Myeloproliferative Neoplasms (MPN)

The aims of the SWG are furthering collaboration and sharing knowledge between centers involved in the management of MPN, a focus to develop centers and clinicians who would be willing to host visiting staff for sabbaticals or learning experiences was…

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

Scientific Program Committee, EHA2025 Congress

Current committee members
Martin Dreyling, Germany (Chair)
Brian Huntly, United Kingdom (Past Chair)
Meritxell Alberich Jordà, Czechia (Chair elect)
Paolo Corradini, Italy (Local representative)
Gabriela Baerlocher, Switzerland
Valentine Brousse, France
Mattia D'Agostino, Italy
Mariane de Montalembert, France
Jordi Esteve, Spain
Thierry Facon, France
Thoas Fioretos, Sweden
Krzystof Giannopoulos, Poland
Shahram Kordasti, United Kingdom
Georg…

Read more

EHA-NSHBT Sickle Cell Disease Webinar

EHA and the Topics-in-Focus Taskforce on Hemoglobinopathies are working with the Nigerian Society of Haematology and Blood Transfusion (NSHBT) to organize a webinar on Sickle Cell Disease (SCD).

Read more

Be part of the EHA community

How you can take an active role and help drive EHA's direction. As a membership organization, EHA is dependent on the dedication of its board and committee members.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

Read more

CAR NK-cells project, February 2025 update

A project update from Dr Ciprian Tomuleasa. We successfully designed and tested in vitro CAR T and CAR NK cells, transfected with the iCas9 suicide trigger.

Read more